2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jennifer Woyach, MD, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia.
Jennifer Woyach, MD, associate professor, The Ohio State University Comprehensive Cancer Center—James, discusses the results of the ELEVATE-TN trial in patients with treatment-naïve chronic lymphocytic leukemia (CLL).
The ELEVATE-TN study examined chlorambucil/obinutuzumab (Gazyva) versus acalabrutinib (Calquence) alone versus acalabrutinib plus obinutuzumab—a trial that led to the FDA approval of acalabrutinib, explains Woyach. Acalabrutinib alone and acalabrutinib/obinutuzumab had significantly improved progression-free survival (PFS) along with a 2-year PFS rate of about 90%, according to Woyach.
There appears to be a beneficial trend with the addition of obinutuzumab to acalabrutinib, which was predicted in preclinical studies. Additionally, obinutuzumab is a superior antibody compared with rituximab (Rituxan), says Woyach. The data need to mature before it is known which patient populations with CLL benefit from the addition of obinutuzumab, concludes Woyach.
Related Content: